Abstract
In cytology, it is often difficult to make a definite diagnosis of endometrial cancer. In order to devise a new supplementary method, using flow cytometry we analyzed the reactivities of endometrial cells with two monoclonal antibodies (MSN-1 and MSN-3), both of which are strongly reactive to endometrial cancer cells. Employing either or both antibodies in flow cytometry, we investigated the usefulness of this analysis for distinguishing endometrial cancer cells from normal endometrial cells. Results revealed a low positive rate for normal endometrium: 9.2% with MSN-1 and 5.0% with MSN-3. In contrast, for endometrial cancer the positive rate was high: 81.2% with MSN-1 and 43.8% with MSN-3. Combined analysis with both antibodies increased the positive rate for endometrial cancer to 93.7%. These results suggest that analysis by flow cytometry employing MSN-1 and MSN-3 may have a diagnostic value for endometrial cancer. We are also investigating the usefulness of two-color analysis using these antibodies.
| Original language | English |
|---|---|
| Pages (from-to) | 2476-2483 |
| Number of pages | 8 |
| Journal | Nippon rinsho. Japanese journal of clinical medicine |
| Volume | 50 |
| Issue number | 10 |
| Publication status | Published - 1992 Oct |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Development of a new supplementary diagnostic method for endometrial cancer by flow cytometry employing anti-endometrial cancer antibody, MSN-1 and MSN-3. / Tsukazaki, K.; Kobiki, K.; Hasegawa, K.; Sakayori, M.; Nozawa, S.
In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 50, No. 10, 10.1992, p. 2476-2483.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Development of a new supplementary diagnostic method for endometrial cancer by flow cytometry employing anti-endometrial cancer antibody, MSN-1 and MSN-3
AU - Tsukazaki, K.
AU - Kobiki, K.
AU - Hasegawa, K.
AU - Sakayori, M.
AU - Nozawa, S.
PY - 1992/10
Y1 - 1992/10
N2 - In cytology, it is often difficult to make a definite diagnosis of endometrial cancer. In order to devise a new supplementary method, using flow cytometry we analyzed the reactivities of endometrial cells with two monoclonal antibodies (MSN-1 and MSN-3), both of which are strongly reactive to endometrial cancer cells. Employing either or both antibodies in flow cytometry, we investigated the usefulness of this analysis for distinguishing endometrial cancer cells from normal endometrial cells. Results revealed a low positive rate for normal endometrium: 9.2% with MSN-1 and 5.0% with MSN-3. In contrast, for endometrial cancer the positive rate was high: 81.2% with MSN-1 and 43.8% with MSN-3. Combined analysis with both antibodies increased the positive rate for endometrial cancer to 93.7%. These results suggest that analysis by flow cytometry employing MSN-1 and MSN-3 may have a diagnostic value for endometrial cancer. We are also investigating the usefulness of two-color analysis using these antibodies.
AB - In cytology, it is often difficult to make a definite diagnosis of endometrial cancer. In order to devise a new supplementary method, using flow cytometry we analyzed the reactivities of endometrial cells with two monoclonal antibodies (MSN-1 and MSN-3), both of which are strongly reactive to endometrial cancer cells. Employing either or both antibodies in flow cytometry, we investigated the usefulness of this analysis for distinguishing endometrial cancer cells from normal endometrial cells. Results revealed a low positive rate for normal endometrium: 9.2% with MSN-1 and 5.0% with MSN-3. In contrast, for endometrial cancer the positive rate was high: 81.2% with MSN-1 and 43.8% with MSN-3. Combined analysis with both antibodies increased the positive rate for endometrial cancer to 93.7%. These results suggest that analysis by flow cytometry employing MSN-1 and MSN-3 may have a diagnostic value for endometrial cancer. We are also investigating the usefulness of two-color analysis using these antibodies.
UR - http://www.scopus.com/inward/record.url?scp=0026939040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026939040&partnerID=8YFLogxK
M3 - Article
C2 - 1280307
AN - SCOPUS:0026939040
VL - 50
SP - 2476
EP - 2483
JO - Nihon rinsho. Japanese journal of clinical medicine
JF - Nihon rinsho. Japanese journal of clinical medicine
SN - 0047-1852
IS - 10
ER -